Cargando…
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M mutation leads to resistance to most clinically available EGFR TKIs. Third-generation EGFR TKIs against the T790M mutation hav...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830020/ https://www.ncbi.nlm.nih.gov/pubmed/27071706 http://dx.doi.org/10.1186/s13045-016-0268-z |